Tirzepatide CVOT Evidence: What the Cardiovascular Outcome Data Shows

You've read about semaglutide's heart results, and now you want to know whether tirzepatide has the same data

It's a fair and practical question. Semaglutide (Wegovy) earned considerable attention when the SELECT trial published results showing a 20% relative reduction in major adverse cardiovascular events among adults with obesity and pre-existing cardiovascular disease, without diabetes being a requirement. That was a landmark finding, and it shifted how clinicians and regulators think about GLP-1 medicines beyond their weight-loss effects.

Tirzepatide's position is different at this moment. The dedicated tirzepatide CVOT, called SURMOUNT-MMO, is still running. It is a large randomised controlled trial enrolling adults with obesity and established cardiovascular disease, with a primary endpoint of MACE, meaning heart attack, stroke and cardiovascular death. Full outcome data from SURMOUNT-MMO has not yet been published. What exists in the interim is a body of indirect evidence: cardiovascular risk-factor improvements seen across the SURMOUNT weight-loss programme, including reductions in blood pressure, triglycerides, waist circumference and markers of metabolic risk. These are encouraging signals, but they are not the same as a completed CVOT demonstrating endpoint reduction.

One practical thing you can do right now: check the SURMOUNT-MMO trial detail page for the latest status update, it takes under a minute and keeps you current without having to search through primary sources.

The distinction matters. Clinicians reading the evidence know that improvements in surrogate markers do not automatically translate to reductions in hard cardiovascular events, which is precisely why the CVOT is being run. If you want to understand more about how tirzepatide works and what the licensed formulations involve, the tirzepatide L page covers the specifics of that version in detail. Tirzepatide's mechanism (activating both GIP and GLP-1 receptors) is different from semaglutide's single GLP-1 pathway, and whether that dual action produces a distinct cardiovascular effect is a genuinely open scientific question until SURMOUNT-MMO reports.

What the SURMOUNT programme does tell us about cardiovascular risk factors

Across the SURMOUNT trials, tirzepatide consistently improved several measurements that clinicians use as proxies for cardiovascular risk. In SURMOUNT-1, participants without diabetes achieved average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, reductions of that scale reliably affect blood pressure, lipid profiles and insulin sensitivity, all of which carry independent cardiovascular relevance. The tirzepatide overview page sets out the SURMOUNT-1 findings in more detail.

NICE's appraisal committee, in their review for TA1026, discussed the cardiovascular evidence base candidly. The committee noted that direct head-to-head cardiovascular outcome data for tirzepatide was not available at the time of appraisal, and that the evidence supporting its recommendation rested substantially on the weight-loss and metabolic improvements seen in the SURMOUNT programme, cross-referenced against the broader GLP-1 class evidence. You can read the committee's reasoning in NICE's published appraisal of tirzepatide (TA1026).

For people with a history of cardiovascular disease who are considering tirzepatide for weight management through a private route like Mounjaro, this context is relevant to the conversation with a prescriber. The cardiovascular risk-factor data provides reasonable grounds for optimism; the outcome trial will provide certainty. Those are two different levels of evidence, and it is worth understanding which one you are citing when you read about tirzepatide and heart health online.

How this compares to what we know about semaglutide's cardiovascular data

Semaglutide's cardiovascular track record now includes more than one completed major trial. In addition to SELECT (obesity, no diabetes, 20% MACE reduction published in the New England Journal of Medicine), earlier trials in the diabetes setting (SUSTAIN-6 and PIONEER-6) also demonstrated cardiovascular safety, building a progressively stronger evidence base over several years. That history is why semaglutide (Wegovy) has also received a separate UK licence for reducing cardiovascular event risk in eligible adults with obesity.

Tirzepatide is earlier in that process. This does not mean the cardiovascular profile is worse, it means the long-term data is simply not yet available. The Mounjaro or tirzepatide comparison page covers how the two medicines sit alongside each other on the current evidence. When SURMOUNT-MMO reports, it will materially update this picture, and it is one of the most-watched trials in metabolic medicine right now.

For a sense of current private treatment costs while you are weighing up your options, the Mounjaro cost and pricing page explains what UK private treatment typically involves. Understanding that context sits alongside (not instead of) a proper clinical assessment of cardiovascular history and suitability.

What a prescriber will actually assess when cardiovascular history is part of your picture

For anyone with existing cardiovascular disease or significant cardiovascular risk factors, a prescriber reviewing a tirzepatide consultation will want to know the specifics: the nature of the diagnosis, current medications, blood pressure readings, and any conditions that would affect suitability. The licensed eligibility criteria for Mounjaro cover adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as hypertension or dyslipidaemia, both of which intersect directly with cardiovascular risk.

A prescriber's job is not simply to check the BMI number. It is to look at the full clinical picture, including cardiovascular history, and decide whether the benefit-risk balance supports treatment. The weight-loss treatment overview explains how that assessment works in practice at a regulated private pharmacy. At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician who reviews the detail, not automated software passing queries along.

The cardiovascular outcome data for tirzepatide will strengthen further as SURMOUNT-MMO completes. In the meantime, the decision about whether Mounjaro is right for someone with cardiovascular risk factors belongs in a proper clinical conversation. If you are ready to have that conversation, you can start your free consultation with our prescribing team and have your case reviewed the same day.